Molecular Partners AG (SWX:MOLN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 114.13M |
| Revenue (ttm) | 2.23M |
| Net Income (ttm) | -59.49M |
| Shares Out | 36.87M |
| EPS (ttm) | -1.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,796 |
| Average Volume | 33,593 |
| Open | 2.940 |
| Previous Close | 3.095 |
| Day's Range | 2.920 - 3.065 |
| 52-Week Range | 2.700 - 7.390 |
| Beta | 0.57 |
| RSI | 49.33 |
| Earnings Date | Aug 25, 2025 |
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D... [Read more]
Financial Performance
In 2024, Molecular Partners AG's revenue was 4.97 million, a decrease of -29.38% compared to the previous year's 7.04 million. Losses were -54.04 million, -12.81% less than in 2023.
Financial StatementsNews
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 22, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-sta...
Molecular Partners to cut jobs, cash reach now anticipated to extend into 2028
Molecular Partners to cut workforce by a quarter
Swiss biotech firm Molecular Partners said on Tuesday that it plans to reduce its workforce by up to 40 positions, or around 24%, as part of a strategic review to boost operational efficiency and focu...
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...
Molecular Partners to Present at Upcoming Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-bu...
Molecular Partners reports Q1 results
Molecular Partners: Sluggish Progress But Worth Monitoring (Rating Downgrade)
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotec...
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-...
Molecular Partners to hold three poster presentations at AACR 2025
Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer
Molecular Partners Publishes Invitation to Annual General Meeting 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-...
Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript
Molecular Partners GAAP EPS of -CHF1.59, revenue of CHF5.0M
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotec...
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-b...
Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs
Molecular Partners & Orano Med join hands for alpha radio-therapies for cancer
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-...
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-b...
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected...
Molecular Partners prices $20M offering
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biote...